Research · Regulatory news

Orforglipron gains UK regulatory approval for type 2 diabetes

By Erik Jones · Aug 11, 2026 · 5 min read

The UK just became the first country in Europe to authorise orforglipron, a once-daily GLP-1 pill, for type 2 diabetes and weight management. On August 10, 2026, Britain’s medicines regulator, the MHRA, authorized orforglipron, sold as Foundayo, for adults whose type 2 diabetes is not well controlled, alongside diet and exercise, either on its own or with other diabetes medicines. This is a decision made for people, based on human clinical trials, not an early lab finding.

Here’s what that means and what it doesn’t.

What orforglipron is

Orforglipron belongs to a drug class called GLP-1 receptor agonists. You may already know this family by brand names like Ozempic (semaglutide), an injection. Mounjaro (tirzepatide) is a close relative that acts on GLP-1 and a second hormone. Orforglipron works the way GLP-1 drugs do: it copies the action of a gut hormone (GLP-1) that your body makes after eating, which tells your brain you’re full and helps your pancreas release insulin when blood sugar is high.

The difference that matters here is the form. Orforglipron is a pill, taken once a day, at any time, with no food or water rules. Most GLP-1 medicines require an injection and some require fasting or timing around meals. Oral semaglutide is already available in the UK as a daily pill, but it has to be taken on an empty stomach with a small sip of water. The MHRA says orforglipron can be taken at any time of day with no food or water restrictions.

Dosing starts low and increases slowly: 0.8 mg, then step up through 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg. That gradual schedule is standard practice for this drug class and is meant to reduce side effects as the body adjusts.

What the evidence actually shows

According to Lilly, the drug’s maker, the type 2 diabetes authorisation rests on trials from its ACHIEVE program (ACHIEVE-1, -2, -3 and -5). These were randomized controlled trials in people with type 2 diabetes, not animal studies and not a single uncontrolled report. A few of the headline results:

• In one trial (ACHIEVE-1), people whose diabetes wasn’t controlled by diet and exercise alone saw their HbA1c, the standard blood test for average blood sugar over about three months, drop by about 1.3 to 1.6 percentage points over 40 weeks, from an average starting A1C of 8.0%.
• In a head-to-head trial against dapagliflozin (ACHIEVE-2), a widely used diabetes pill, Lilly reports that orforglipron produced a larger HbA1c drop.
• In ACHIEVE-3, the first head-to-head trial of two GLP-1 pills, both orforglipron doses lowered HbA1c more than oral semaglutide at its approved diabetes doses (1.9 and 2.2 points versus 1.1 and 1.4 points over 52 weeks).

Those are real, measured outcomes in people with the condition, which is a meaningfully higher bar than the animal and cell-based research that often gets inflated in health reporting. The MHRA lists the most common side effects as nausea, constipation, diarrhea, vomiting, indigestion and abdominal pain, consistent with what’s seen across this entire drug class.

What this approval is not

It is not an NHS funding decision. Foundayo is authorized for sale, meaning a doctor can legally prescribe it, but it is not currently available free or subsidized through the NHS. The National Institute for Health and Care Excellence (NICE) decides separately whether the health service should pay for a medicine. NICE is assessing orforglipron for weight management, and no NHS funding decision has been made for its use in type 2 diabetes. For now, UK patients who want it need a private prescription from a qualified prescriber, and they’ll pay the private cost.

It is also not a statement that this drug is right for any particular person. Whether orforglipron suits someone depends on their medical history, other medications, and other clinical factors a prescriber has to weigh. This article is not medical advice, and it should not be read as a recommendation to start, stop, or switch any diabetes treatment. That conversation belongs with your own doctor or diabetes care team.

Why it matters beyond the UK

Regulatory approval in one country is not approval everywhere. In the US, orforglipron (Foundayo) is approved only for weight management; Lilly has filed for the diabetes use there, and a decision is pending. In October 2026 the EU’s medicines committee recommended approving it for both weight management and type 2 diabetes, with a final European Commission decision still to come. For people who have wanted the metabolic benefits of a GLP-1 drug but have avoided or struggled with needles, a once-daily pill with no meal-timing restrictions removes a real practical barrier, if and when it becomes affordable and accessible where they live.

What to watch next: whether NICE recommends NHS funding, whether the European Commission confirms the EU authorisation, and how the FDA rules on the diabetes filing. We do not yet know the answer to any of these questions, and nothing here should be read as a prediction that they will.

Primary source: MHRA’s own announcement, https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes. Trial results are from Eli Lilly’s ACHIEVE releases; EU and US status from the EMA and FDA announcements listed in the sources.

Not medical advice. Educational summary of published research. Last reviewed Oct 27, 2026.